COMP <GO>
DERM vs JNJ // EV/EBITDA & P/E VALUATION
Journey Medical Corporation (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: DERM 1
— JNJ 9
■ METRIC PARITY
LAST: $4.79 (-7.35%) • MKT CAP: $145.9M
valuation
—
LAST: $270.56 (-0.97%) • MKT CAP: $657.68B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DERM VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DERM | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 65.80% | 67.90% | -2.10 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -19.50% | 25.50% | -45.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.15% | 2.97% | -11.12 | JNJ | /fcf-yield <GO> |
| Operating Margin | -13.30% | 34.70% | -48.00 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -18.70% | 28.50% | -47.20 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 11.10% | 6.00% | +5.10 | DERM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.74 | 5.59 | -4.85 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.5 | 59.1 | -18.60 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $145.9M | $657.68B | -$657.53B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DERM REV | JNJ REV | DERM GROSS % | JNJ GROSS % | DERM FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $61.2M | $94.19B | 65.8% | 67.9% | -$12.4M | $19.70B |
| FY 2024 | $55.1M | $88.82B | 62.1% | 69.1% | -$9.1M | $19.84B |
| FY 2023 | $59.7M | $85.16B | — | — | $5.2M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DERM // BETA —
JNJ // BETA 1.08